Emory Vaccine Center

Mission Statement


The Emory Vaccine Center (EVC) is making fundamental advances in immunology, virology and vaccine research to search for life saving cures against the world's most threatening diseases plaguing millions of individuals around the globe. Comprehensive expertise in scientific, technological, and clinical research distinguishes the EVC as a world leader in the discovery, development and clinical analysis of safe, effective and affordable vaccines. Housed in one of the largest academic centers ever created to investigate new vaccine strategies, the 75,000-square-foot EVC fosters a deeper understanding of the complexities of infectious diseases, cancer biology and vaccine development. Dr. Rafi Ahmed, an internationally renowned scientist in viral pathogenesis and immunity and one of the world's leading experts on T-cell memory, leads the Center. Dr. Ahmed has been instrumental in shaping EVC's research agenda that encompasses a continuum of basic, clinical and translational science. The Center's Affiliation with Emory's Emory National Primate Research Center also supports research at the forefront of immunology strategy and vaccine development. Long recognized as one of the leading centers for biomedical and biobehavioral research with non-human primates, Emory is home to a broad range of molecular and cellular research. The Hope Clinic of the Emory Vaccine Center serves as the clinical arm, directing all current on-site clinical vaccine trials. As one of eight participating national sites in the NIAID's prestigious Vaccine Trials Evaluation Units (VTEUs), the Clinic plays a vital role in advancing the most promising pre-clinical vaccine research into human clinical trials.

Vaccine Center News

Max Cooper Prize in Immunology

Emory Max Cooper Prize In Immunology

Hadyn Kissick awarded Immune response grant

School of Medicine researcher awarded $1.25 million grant to study immune response to cancer

Dr. Mary Galinski retirement announcement

Emory Professor Retires, Leaves Legacy of Malaria Advances to Improve Global Health

2022 Hanna Gray Fellow

25 Early Career Scientists Become HHMI Hanna Gray Fellows

Tuberculosis Bacterium

NIH Funds New Tuberculosis Research Advancement Centers

Picture of Cheryl Day

Cheryl Day to Direct AIDS Clinical Trials Group (ACTG) Network as Lab Director for Immunology Specialty Laboratory (ISL)

Picture of Covid virus

COVID-19 survivors may possess wide-ranging resistance to the disease